Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 5/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651667 | 0.88 | EPHX2 (0.51) | EPHX2 | |
| Trifluoroacetic Acid SCHEMBL30618995 | 0.82 | CYP2D6 (0.40) | GPR6HRH4 | |
| Trifluoroacetic Acid SCHEMBL26599430 | 0.82 | CYP2D6 (0.40) | GPR6HRH4 | |
| Trifluoroacetic Acid SCHEMBL2385688 | 0.81 | EPHX2 (0.47) | EPHX2GPR6HRH4HRH3 | |
| SCHEMBL31651660 | 0.75 | EPHX2 (0.62) | EPHX2 | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL26600776 | 0.73 | KDM4E (0.66) | EPHX2HRH4HRH3 | |
| SCHEMBL31651904 | 0.73 | GPR119 (0.53) | HRH3 | |
| SCHEMBL31651713 | 0.72 | EPHX2 (0.55) | EPHX2 | |
| Trifluoroacetic Acid SCHEMBL6749589 | 0.71 | NEK2 (0.54) | EPHX2HRH4HRH3 | |
| SCHEMBL12949682 | 0.71 | CYP1A2 (0.48) | SCDHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | EPHX2 703/4885SCD 14/4885GPR6 1120/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | EPHX2 703/4885SCD 14/4885GPR6 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.